Loading...
Loading...
Onyx Pharmaceuticals, Inc.
ONXX today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma.
The company has an agreement with the U.S. Food and Drug Administration for a Special Protocol Assessment and has received Scientific Advice from the European Medicines Agency on the design and planned analysis of the ASPIRE trial.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in